Evidence map›Paper›PMID 42491403›Full record

ArticleFrontiers in cell and developmental biology2026

Ophthalmic screening in phakomatoses.

Bijal Kikani, Sarah Stanley, Aparna Ramasubramanian

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bijal Kikani *Medical College of Wisconsin, Milwaukee, WI, United States.
Sarah Stanley *Medical College of Wisconsin, Milwaukee, WI, United States.
Aparna RamasubramanianMedical College of Wisconsin, Milwaukee, WI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phakomatoses are a heterogenous group of congenital neurocutaneous syndromes that are associated with a wide range of ocular and systemic presentations. The ocular conditions are important to consider as they may be asymptomatic early on, but progress to irreversible vision loss. Due to the variability of disease presentation, timely diagnosis is crucial to preserve visual outcomes. This article provides a comprehensive review of literature on nine major phakomatoses, including Neurofibromatosis type 1, Neurofibromatosis type 2, Tuberous Sclerosis complex, Sturge Weber syndrome, Von Hippel-Lindau, Ataxia Telangiectasia, Basal Cell Nevus Syndrome, Wyburn-Mason syndrome, and PHACE syndrome, which are commonly treated by ophthalmologists and other eye care professionals. Across these syndromes, some common vision threatening manifestation include glaucoma, optic pathway gliomas, and retinal hamartomas, with variability in the age of onset and disease progression. This article aims to provide syndrome specific screening guidelines to allow early detection of ocular pathology and promote multi-disciplinary care among ophthalmologists, pediatricians, and other providers to decrease visual morbidities and improve overall patient outcomes.

Indexed as

multi-disciplinary careneurocutaneous syndromesneurofibromatosisophthalmic screeningphakomatosesscreeningtuberous sclerosis

Identifiers

PMID42491403
PMCPMC13376734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.